HILDEN, Germany and LONDON, January 30, 2017 /PRNewswire/--
Bioinformatics content knowledgebase will enable interpretation for 100,000 Genomes Project
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA)
The 100,000 Genomes Project will use QIAGEN's HGMD Online Professional solution, which is part of the QIAGEN Clinical Insight (QCI) portfolio of solutions for the interpretation of complex genomic data, to support scientists, clinicians and researchers in 13 NHS Genomic Medicine Centres for clinical reporting and interpretation.
"Rare and hereditary diseases can lock patients, families and healthcare providers in a long, difficult diagnostic odyssey, and 100,000 Genomes is a cutting-edge NHS program to gather and analyze whole genomes from a large cohort of patients in search of causes and future treatments," said Dr. Laura Furmanski, Senior Vice President and Head of QIAGEN's Bioinformatics Business Area. "We are honored to deepen our collaboration with Genomics England. QIAGEN's industry-leading bioinformatics solutions, including cloud-based HGMD content, will help 100,000 Genomes derive actionable insights from a massive pool of next-generation sequencing data. We are pleased to be selected."
Click here for the full press release
Investor Relations John Gilardi +49-2103-29-11711 e-mail: ir@QIAGEN.com Public Relations Dr. Thomas Theuringer +49-2103-29-11826 e-mail: pr@QIAGEN.com
Katrina Nevin-Ridley Director of Communications Email: email@example.com Phone: +44(0)207-882-6493 @GenomicsEngland #genomes100k
SOURCE QIAGEN N.V.
Subscribe to our Free Newsletters!
Malaria is a dangerous disease with lethal consequences that requires protective measures for ...
Merkel cell carcinoma is a rare and a highly aggressive primary skin cancer that grows rapidly and ...
Vitrectomy is a surgical procedure performed to remove a part or whole of the vitreous humor ...View All